Aurinia Pharmaceuticals
Market Cap
CA$2.8b
Last Updated
2020/02/16 23:54 UTC
Data Sources
Company Financials +
Executive Summary
Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of various diseases in the United States and China.
Rewards
Risk Analysis
Snowflake Analysis
Flawless balance sheet with exceptional growth potential.
Share Price & News
How has Aurinia Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: AUP's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
-3.2%
AUP
-1.2%
CA Biotechs
0.6%
CA Market
1 Year Return
184.2%
AUP
-37.0%
CA Biotechs
5.8%
CA Market
Return vs Industry: AUP exceeded the Canadian Biotechs industry which returned -37% over the past year.
Return vs Market: AUP exceeded the Canadian Market which returned 5.8% over the past year.
Shareholder returns
| AUP | Industry | Market | |
|---|---|---|---|
| 7 Day | -3.2% | -1.2% | 0.6% |
| 30 Day | -5.7% | 2.9% | 0.5% |
| 90 Day | 226.1% | 103.9% | 3.6% |
| 1 Year | 184.2%184.2% | -37.0%-37.0% | 9.1%5.8% |
| 3 Year | 416.7%416.7% | 58.0%58.0% | 15.4%5.0% |
| 5 Year | 426.6%426.6% | 14.4%14.4% | 33.6%14.0% |
Price Volatility Vs. Market
How volatile is Aurinia Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall St
Does Aurinia Pharmaceuticals Inc. (TSE:AUP) Have A Volatile Share Price?1 month ago | Simply Wall St
Aurinia Pharmaceuticals's (TSE:AUP) Wonderful 760% Share Price Increase Shows How Capitalism Can Build Wealth1 month ago | Simply Wall St
Have Aurinia Pharmaceuticals Inc. (TSE:AUP) Insiders Been Selling Their Stock?Valuation
Is Aurinia Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: AUP (CA$24.75) is trading below our estimate of fair value (CA$94.95)
Significantly Below Fair Value: AUP is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: AUP is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: AUP is unprofitable, so we can't compare its PE Ratio to the Canadian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate AUP's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: AUP is overvalued based on its PB Ratio (14.2x) compared to the CA Biotechs industry average (3.7x).
Next Steps
Future Growth
How is Aurinia Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
58.2%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AUP is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.4%).
Earnings vs Market: AUP is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: AUP's is expected to become profitable in the next 3 years.
Revenue vs Market: AUP's revenue (62.1% per year) is forecast to grow faster than the Canadian market (4.9% per year).
High Growth Revenue: AUP's revenue (62.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: AUP's Return on Equity is forecast to be very high in 3 years time (57.7%).
Next Steps
Past Performance
How has Aurinia Pharmaceuticals performed over the past 5 years?
-28.7%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: AUP is currently unprofitable.
Growing Profit Margin: AUP is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: AUP is unprofitable, and losses have increased over the past 5 years at a rate of -28.7% per year.
Accelerating Growth: Unable to compare AUP's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AUP is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (66.2%).
Return on Equity
High ROE: AUP has a negative Return on Equity (-50.07%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Next Steps
Financial Health
How is Aurinia Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: AUP's short term assets ($138.6M) exceed its short term liabilities ($13.5M).
Long Term Liabilities: AUP's short term assets ($138.6M) exceed its long term liabilities ($13.6M).
Debt to Equity History and Analysis
Debt Level: AUP is debt free.
Reducing Debt: AUP had no debt 5 years ago.
Balance Sheet
Inventory Level: AUP has a low level of unsold assets or inventory.
Debt Coverage by Assets: Insufficient data to determine if AUP's debt is covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: AUP has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: AUP has sufficient cash runway for 1.2 years if free cash flow continues to reduce at historical rates of -30.7% each year.
Next Steps
Dividend
What is Aurinia Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate AUP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate AUP's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if AUP's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if AUP's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of AUP's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
2.5yrs
Average management tenure
CEO
Peter Greenleaf (49yo)
0.8yrs
Tenure
Mr. Peter S. Greenleaf, M.B.A., has been Chief Executive Officer and Director of Aurinia Pharmaceuticals Inc. since April 29, 2019. He has been a Director at Antares Pharma, Inc. since December 13, 2018. H ...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder & COO | 0yrs | US$702.00k | 0.15% $4.2m | |
| CFO & Secretary | 21.8yrs | US$680.62k | 0.063% $1.8m | |
| Executive Vice President of Corporate Development | 2.8yrs | US$963.41k | 0.077% $2.1m | |
| 0.8yrs | US$1.80m | 1.02% $28.1m | ||
| Chief Medical Officer | 6.4yrs | US$881.21k | 0.25% $6.9m | |
| CEO & Director | 0.8yrs | no data | 0.0075% $206.1k | |
| Senior Vice President of Corporate Communications & Investor Relations | 0yrs | no data | no data | |
| Chief Corporate Compliance Officer | 2.6yrs | no data | 0.0034% $94.1k | |
| Senior Vice President of Global Clinical Operations | 2.1yrs | no data | 0.0018% $49.5k | |
| Senior VP of Clinical & Medical Affairs | 2.5yrs | no data | no data |
2.5yrs
Average Tenure
54yo
Average Age
Experienced Management: AUP's management team is considered experienced (2.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 0.8yrs | no data | 0.0075% $206.1k | |
| Chairman of the Board | 0.8yrs | US$126.62k | 0.018% $495.0k | |
| Independent Director | 2yrs | US$175.41k | no data | |
| Member of Scientific Advisory Board | 0yrs | no data | no data | |
| Member of Scientific Advisory Board | 0yrs | no data | no data | |
| Member of Transplant Advisory Board & Scientific Advisory Board | 0yrs | no data | no data | |
| Independent Director | 2yrs | US$165.10k | 0.0031% $86.6k | |
| Member of the Clinical Advisory Board | 0yrs | no data | no data | |
| Member of the Scientific Advisory Board & Clinical Advisory Board | 0yrs | no data | no data | |
| Independent Director | 0.7yrs | no data | no data |
0.8yrs
Average Tenure
68yo
Average Age
Experienced Board: AUP's board of directors are not considered experienced ( 0.8 years average tenure), which suggests a new board.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: AUP insiders have sold more shares than they have bought in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 6.4%.
Top Shareholders
Company Information
Aurinia Pharmaceuticals Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Aurinia Pharmaceuticals Inc.
- Ticker: AUP
- Exchange: TSX
- Founded:
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: CA$2.767b
- Shares outstanding: 111.80m
- Website: https://www.auriniapharma.com
Number of Employees
Location
- Aurinia Pharmaceuticals Inc.
- 4464 Markham Street
- Suite 1203
- Victoria
- British Columbia
- V8Z 7X8
- Canada
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| AUP | TSX (The Toronto Stock Exchange) | Yes | Common Shares | CA | CAD | Jan 1999 |
| IKAP | DB (Deutsche Boerse AG) | Yes | Common Shares | DE | EUR | Jan 1999 |
| AUPH | NasdaqGM (Nasdaq Global Market) | Yes | Common Shares | US | USD | Jan 1999 |
| 0UJF | LSE (London Stock Exchange) | Yes | Common Shares | GB | CAD | Jan 1999 |
Biography
Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of various diseases in the United States and China. The company is involved in developing voclosporin, an investigational drug for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/02/16 23:54 |
| End of Day Share Price | 2020/02/14 00:00 |
| Earnings | 2019/09/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.